U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358780) titled 'Remibrutinib in Real-world Clinical Practice - a US Sub-study' on Jan. 13.
Brief Summary: Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib. The primary aim of this study is to gather real-world effectiveness and safety data for remibrutinib, a new treatment option, covering a broader, real-world clinical practice population.
Study Start Date: Jan. 30
Study Type: OBSERVATIONAL
Condition:
Chronic Spontaneous Urticaria
Recruitment Status: NOT_YET_RECRUITING
Sponsor...